Vindira Sankar

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi et al. · Journal of Clinical Oncology · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab

David F. McDermott, Charles G. Drake, Mario Sznol et al. · Journal of Clinical Oncology · 2015 · 443 citations

Medicine, Oncology, Pharmacotherapy +17

Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538).

Joseph F. Grosso, Christine E. Horak, David Inzunza et al. · Journal of Clinical Oncology · 2013 · 159 citations

Life Sciences, Immunology, Oncology +17

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

Julie R. Brahmer, Leora Horn, Scott Antonia et al. · Journal of Clinical Oncology · 2013 · 74 citations

Medicine, Oncology, Pharmacology +17

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

Charles G. Drake, David F. McDermott, Mario Sznol et al. · Journal of Clinical Oncology · 2013 · 55 citations

Medicine, Oncology, Pharmacotherapy +17